NCT04421066

Brief Summary

In this study genomic, proteomic and histological technologies for the search and characterization of epigenetic modifications and molecular or protein markers, useful in the diagnosis and progression of peri-implant diseases and prevention of implant failure will be used.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 29, 2019

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 1, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 21, 2021

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2022

Completed
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

2.7 years

First QC Date

June 1, 2020

Last Update Submit

February 24, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Differences in histological characteristics in peri-implantitis subjects compared to healthy subjects, ie, presence and amount of inflammatory cells and bacteria.

    Gingival and blood samples collected from healthy subjects and subjects with peri-implantitis (including failing implants) will be used to determinate histological characteristics associated with peri-implantitis.

    1 day

  • Differences in epigenetic characteristics analyzing DNA methylation in peri-implantitis subjects compared to healthy subjects.

    Gingival and blood samples collected from healthy subjects and subjects with peri-implantitis (including failing implants) will be used to determinate epigenetic characteristics associated with peri-implantitis.

    1 day

Secondary Outcomes (5)

  • Relation between peri-implant diseases and epigenetic modifications in terms of periodontal pocket depth.

    1 day

  • Relation between peri-implant diseases and epigenetic modifications in terms of bleeding on probing.

    1 day

  • Relation between peri-implant diseases and epigenetic modifications in terms of clinical attachment level.

    1 day

  • Relation between peri-implant diseases and epigenetic modifications in terms of plaque index.

    1 day

  • Patient-reported outcome measures.

    1 day

Study Arms (2)

Peri-implantitis

Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.

Procedure: Gingival and bone sample collection

Healthy

Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.

Procedure: Healthy individuals

Interventions

Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.

Peri-implantitis

Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.

Healthy

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* Periodontally Healthy Subjects * Peri-implantitis Subjects

You may qualify if:

  • The subjects must have read, understood and signed an informed consent regarding the obtaining of biological samples and participation in the research line of "Oral Health and Systemic Relationship" existing in the Pardiñas Dental Medical Clinic and approved by the ethical committee.
  • The subjects must be between 20-90 years of age.
  • Subjects must be non-smokers or former smokers who have quit smoking for at least one year prior to enrollment in the study.
  • In addition to the general criteria listed, samples of a healthy periodontal subject must meet the following criteria when reviewing their medical and dental history :
  • Subjects do not have or have had a history of periodontal disease, as described in the " 2017 World Workshop on the Classification of Periodontal and Peri- Implant Diseases and Conditions "
  • Samples from a subject with peri-implant disease must meet the following criteria:
  • Samples of subjects who have at least one implant - supported prosthesis for at least 12 months and affected by peri- implant disease according to the " 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions "

You may not qualify if:

  • Samples of pregnant or lactating women at the time of collection.
  • Samples of subjects who were taking antibiotics within 1 month before collection of the sample.
  • Samples of subjects with chronic use of non-steroidal anti-inflammatory drugs for more than 3 weeks at the time of sample collection. The use of aspirin in low doses (≤81 mg / day) will be allowed .
  • Samples from subjects with disease in the mucosa in the area located around the site of sample collection.
  • Samples of subjects with a systemic disease that would exclude the analysis (for example, severe medical problems, bone metabolism disorders, uncontrolled bleeding disorders, depressed immune system, diseases that require the periodic use of steroids, uncontrolled endocrine disorders) .
  • Samples of subjects with a history of local irradiation therapy in the head / neck area.
  • Samples of subjects with a history of having received treatment with intravenous or subcutaneous antiresorptive agents associated with osteonecrosis of the jaw, such as bisphosphonates.
  • Samples of subjects assigned to the healthy group that meet any of the following criteria will be excluded from participation in this study:
  • Root fragments, pericoronaritis, endo-perio lesions, dental abscesses at the site of the biopsy.
  • Presence of BOP in the sample collection site.
  • The samples of the subjects assigned to the peri- implant diseases group that meet any of the following criteria will be excluded from participation in this study if the implants were removed due to:
  • Inadequate position of the implant.
  • Subjects with implants previously treated surgically for peri- implant disease with antibiotics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fundacion Clinica Pardiñas

A Coruña, Galicia, 15003, Spain

Location

Biospecimen

Retention: SAMPLES WITH DNA

Gingival and bone samples

MeSH Terms

Conditions

Peri-Implantitis

Interventions

Chewing Gum

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Plant GumsBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesPlant ExudatesBiological ProductsComplex MixturesCandyFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Simón Pardiñas López, DDS, MS

    Fundación Clínica Pardiñas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

June 1, 2020

First Posted

June 9, 2020

Study Start

January 29, 2019

Primary Completion

October 21, 2021

Study Completion

June 20, 2022

Last Updated

February 26, 2025

Record last verified: 2025-02

Locations